Success rate of Pralsetinib in treating lung adenocarcinoma

Pralsetinib has achieved encouraging success rates in treating lung adenocarcinoma, according to clinical trial results. In a clinical trial called the ARROW study, researchers looked at the efficacy of platinib in patients with advanced or metastatic non-small cell lung cancer with RET gene rearrangements. The results of the study showed that the overall effectiveness of platinib in these patients reached a high level. According to data, more than 20% (approximately 64%) of the patients participating in the trial experienced partial shrinkage or complete disappearance of their tumors. In addition, Platinib demonstrated good tolerability and safety, allowing patients to remain on treatment for longer periods of time.